Capturing autism’s sleep problems with devices nearable and wearable
Next-generation trackers could realize a long-standing research dream: conducting sleep studies in large numbers of autistic people.
Next-generation trackers could realize a long-standing research dream: conducting sleep studies in large numbers of autistic people.
This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.
A careful clinician who prizes evidence, Jeremy Veenstra-VanderWeele is happy to embrace trial failures, as long as he learns from them.
Few studies have tracked how brain structure and function change across adulthood in people with autism. Carper and her colleagues are collecting data to fill this gap.
The findings add to the growing evidence that genes with disparate functions can play similar roles in brain development.
The annual meeting of the International Society for Autism Research in Sweden’s capital — which starts Wednesday — plans to tackle friction over terminology and research priorities.
This month’s issue of the Going on Trial newsletter explores why it’s more fun to have a beer with friends than by yourself — and how that informs an ongoing clinical trial for autism.
The phase 2A trial has its detractors despite positive animal results and is being sponsored by a company that is struggling financially.
If a therapy for autism’s core traits makes it to market, it will likely take one of three forms, the researchers say.
Here is a roundup of news and research for the week of 3 April.